Full Text View
Tabular View
No Study Results Posted
Related Studies
Anti-Arrhythmic Medication v. MRI-Merge Ablation in the Treatment of Ventricular Tachycardia
This study is not yet open for participant recruitment.
Study NCT00721032   Information provided by Johns Hopkins University
First Received: July 21, 2008   Last Updated: July 23, 2008   History of Changes

July 21, 2008
July 23, 2008
August 2008
August 2011   (final data collection date for primary outcome measure)
Freedom from ventricular tachycardia documented by implantable defibrillator cardioverter 6 months post ablation. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00721032 on ClinicalTrials.gov Archive Site
  • inducible arrhythmia at the end of the procedure, [ Time Frame: During procedure ] [ Designated as safety issue: No ]
  • Procedure time [ Time Frame: During procedure ] [ Designated as safety issue: No ]
  • Comparison of endocardial voltage mapping to scar on delayed enhancement MRI images [ Time Frame: During procedure ] [ Designated as safety issue: No ]
  • Complications of the procedure [ Time Frame: 30 days following procedure ] [ Designated as safety issue: Yes ]
Same as current
 
Anti-Arrhythmic Medication v. MRI-Merge Ablation in the Treatment of Ventricular Tachycardia
Anti-Arrhythmic Medication v. MRI-Merge Ablation in the Treatment of Ventricular Tachycardia

Ventricular tachycardia (VT) is a morbid arrhythmia responsible for many sudden deaths and ICD shocks. Despite much progress in the treatment of arrhythmia, VT remains a therapeutic challenge. Most patients with VT have an implantable cardioverter defibrillator (ICD) for secondary prevention of sudden cardiac death, however, an ICD merely treats VT, it does not prevent VT. In patients with recurrent VT and ICD shocks, two strategies are available to decrease the burden of VT. The first is antiarrhythmic drugs, and the second is VT ablation. The aim of this study is to compare the efficacy of antiarrhythmic drugs and VT ablation guided by MRI. VT can sometimes be suppressed with antiarrhythmic medications, however, these are often ineffective, and carry a high burden of side effects. Many forms of VT can be cured by selective destruction of critical electrical pathways with catheter ablation. A major limitation in the ablation of VT, however, is the time required to localize scar tissue and important pathways for targeting of lesions. Magnetic resonance imaging can now obtain reliable images of scar location within the ventricles. Recent advances in electroanatomical mapping systems allow operators to import pre-acquired images into the mapping system. The aim of this study is to examine the feasibility of importing historic MRI scar maps of the ventricles into the electroanatomical system and using such images to guide catheter ablation, as compared to antiarrhythmic drug suppression of VT. We suspect that MRI guidance will be especially useful in patients with "unstable" VT, i.e. VT that causes an abrupt drop in blood pressure, and thus cannot be maintained in the EP lab for mapping and entrainment purposes. Patients referred for VT ablation have ICDs. Through previously completed animal work (Circulation 2004; 110(5): 475-82) and a human trial (2006 Sep 19;114(12):1277-84) we have demonstrated the safety of MRI in the setting of pacemakers and implantable defibrillators using appropriate precautions. Through careful device programming and using MRI sequences with limited energy exposure (specific absorption rate < 2 W/kg) we will study the pre procedural myocardial anatomy of patients enrolled into this study.

The primary endpoint will be lack of VT documented by implantable defibrillator (when present) interrogation or Holter monitoring 6 months post ablation. The secondary endpoints will be comparison of inducible arrhythmia at the end of the procedure, procedure time, comparison of endocardial voltage mapping to scar on delayed enhancement MRI images, and complications in each study arm.

 
 
Interventional
Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Ventricular Tachycardia
  • Procedure: MRI guided VT ablation
  • Drug: Increased dose of amiodarone
  • Experimental: Magnetic resonance imaging (MRI)-guided ablation of ventricular tachycardia.
  • Active Comparator: Anti-arrhythmic group.
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Not yet recruiting
70
August 2012
August 2011   (final data collection date for primary outcome measure)

Inclusion:

  • Current treatment with amiodarone
  • Ischemic or non-ischemic cardiomyopathy
  • Monomorphic ventricular tachycardia at any cycle length, with > 1 occurrence of the same cycle length and morphology, at least one episode needs to be of sufficient duration to result in a shock.
  • No contraindication to up titration of meds or to VT RFA

Exclusion:

  • Primary antiarrhythmic medication other than amiodarone
  • Amiodarone at dose of 600 mg daily or higher
  • Polymorphic VT as culprit rhythm
  • History of metal exposure (welding)
  • Pregnant women
  • Recent myocardial infarction
  • Planned coronary revascularization
  • Implantable cardiac devices not previously tested for safety in the setting of MRI
  • GFR < 30 ml/min
Both
18 Years and older
No
Contact: Charles A Henrikson, MD 410 955 2412 chenriks@jhmi.edu
Contact: Saman Nazarian, MD 410 614 2751 snazarian@jhmi.edu
 
 
NCT00721032
Charles Henrikson, MD, Johns Hopkins University
NA_00011012
Johns Hopkins University
 
 
Johns Hopkins University
July 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP